Papers

1

Total Citations

9

H-Index

1

About

Dr. Naixin Liang is a leading translational researcher in thoracic oncology, whose work centers on the non-invasive detection and molecular characterization of early-stage lung cancer. Her most significant contribution is the development of a cost-effective, non-invasive blood test based on plasma protein functional effector sncRNAs (pfeRNAs). This pioneering approach, detailed in her highly cited 2021 study, demonstrates a remarkable ability to differentiate between benign, suspicious, and malignant pulmonary nodules, addressing a critical clinical challenge in early intervention. By moving beyond traditional imaging limitations, Dr. Liang’s work offers a powerful, accessible tool for reducing unnecessary invasive procedures and improving diagnostic accuracy. Her research has garnered substantial attention, with this key paper accumulating 9 citations, reflecting its immediate impact on the field. Dr. Liang’s achievements position her at the forefront of liquid biopsy innovation, providing a promising pathway toward more precise, patient-friendly lung cancer screening and management.

Research Focus

Key Achievements

1
H-Index
1
Papers
9
Total Citations
9
Avg Citations/Paper
🏆 Most Cited Paper
A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones
9 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 21
🏛 Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago